Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

Zacks Investment Research News Agency

Yesterday•Zacks Investment Research

Stocks Medium Importance Neutral

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

Halozyme Therapeutics (HALO) came out with quarterly earnings of $2.28 per share, beating the Zacks Consensus Estimate of $1.82 per share. This compares to earnings of $1.54 per share a year ago.

Related Symbols 1

H HALO HALO

Source: Zacks Investment Research

Visit Source

0 0 0

Comment

Comments

No comments yet

Be the first person to comment on this news item.

Category Stocks

Source Zacks Investment Research

Published Yesterday

Likes 0

Comments 0

Shares 0

News ID #2,468

Status Published

This news may have been collected automatically from third-party sources. Please verify important information through the original source and other reliable sources before making any trading or investment decision. This content is provided for informational purposes only and does not constitute financial advice.

Keep comments relevant to the news topic and avoid offensive, promotional, spam, or misleading content.

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

Comments

User Menu